LLY

900.5

-1.77%↓

JNJ

235

+0.06%↑

ABBV

204.27

-0.16%↓

NVS

147.36

-0.22%↓

AZN

184.05

-0.26%↓

LLY

900.5

-1.77%↓

JNJ

235

+0.06%↑

ABBV

204.27

-0.16%↓

NVS

147.36

-0.22%↓

AZN

184.05

-0.26%↓

LLY

900.5

-1.77%↓

JNJ

235

+0.06%↑

ABBV

204.27

-0.16%↓

NVS

147.36

-0.22%↓

AZN

184.05

-0.26%↓

LLY

900.5

-1.77%↓

JNJ

235

+0.06%↑

ABBV

204.27

-0.16%↓

NVS

147.36

-0.22%↓

AZN

184.05

-0.26%↓

LLY

900.5

-1.77%↓

JNJ

235

+0.06%↑

ABBV

204.27

-0.16%↓

NVS

147.36

-0.22%↓

AZN

184.05

-0.26%↓

Home・Aandelen Lijst・LifeStance Health Group Inc

LifeStance Health Group Inc

Open

SectorGezondheidszorg

6.44 -1.08

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

6.41

Max

6.62

Belangrijke statistieken
By Trading Economics
Inkomsten	11M 12M
Verkoop	18M 382M
K/W Sectorgemiddelde	322.5 57.833
EPS	0.089
Winstmarge	3.053
Werknemers	10,961
EBITDA	11M 32M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+58.44% upside

Dividenden
By Dow Jones
Volgende Winsten	6 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-289M 2.5B
Vorige openingsprijs	7.52
Vorige sluitingsprijs	6.44

Nieuwssentiment

By Acuity

100%

331 / 350 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

5.39 / 6.595 Steun & Weerstand

LifeStance Health Group Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

23 mrt 2026, 23:47 UTC

Acquisities, Fusies, Overnames

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23 mrt 2026, 22:55 UTC

Acquisities, Fusies, Overnames

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

23 mrt 2026, 21:51 UTC

Acquisities, Fusies, Overnames

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

23 mrt 2026, 23:59 UTC

Marktinformatie

Global Equities Roundup: Market Talk

23 mrt 2026, 23:59 UTC

Marktinformatie

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

23 mrt 2026, 23:50 UTC

Marktinformatie

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

23 mrt 2026, 23:37 UTC

Marktinformatie

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

23 mrt 2026, 22:42 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Global Equities Roundup: Market Talk

23 mrt 2026, 22:42 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

23 mrt 2026, 22:40 UTC

Acquisities, Fusies, Overnames

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23 mrt 2026, 22:23 UTC

Marktinformatie

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

23 mrt 2026, 22:22 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23 mrt 2026, 22:21 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23 mrt 2026, 22:21 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23 mrt 2026, 22:20 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23 mrt 2026, 22:20 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23 mrt 2026, 22:19 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23 mrt 2026, 22:19 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

23 mrt 2026, 22:18 UTC

Acquisities, Fusies, Overnames

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

23 mrt 2026, 22:15 UTC

Acquisities, Fusies, Overnames

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

23 mrt 2026, 22:08 UTC

Marktinformatie

Ebos Needs to Reset Its Gearing Targets -- Market Talk

23 mrt 2026, 21:42 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

23 mrt 2026, 21:42 UTC

Marktinformatie

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

23 mrt 2026, 21:32 UTC

Winsten

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

23 mrt 2026, 21:32 UTC

Winsten

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

23 mrt 2026, 21:32 UTC

Winsten

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

23 mrt 2026, 21:10 UTC

Belangrijke Nieuwsgebeurtenissen

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

23 mrt 2026, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

23 mrt 2026, 20:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

23 mrt 2026, 20:50 UTC

Marktinformatie

Winsten

Belangrijke Nieuwsgebeurtenissen

Basic Materials Roundup: Market Talk

Peer Vergelijking

Prijswijziging

LifeStance Health Group Inc Prognose

Koersdoel

By TipRanks

58.44% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 10.14 USD 58.44%

Hoogste 12 USD

Laagste 9 USD

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor LifeStance Health Group Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Gebaseerd op 8 analisten die aandelenratings hebben gegeven aan LifeStance Health Group Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

5.39 / 6.595Steun & Weerstand

Recent bearish events outweigh bullish events.

All events are bearish.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over LifeStance Health Group Inc

LifeStance Health Group, Inc., through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy. It treats a range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder. In addition, the company operates an outpatient mental health platform, as well as offers patient care virtually through its online delivery platform or in-person at its centers. LifeStance Health Group, Inc. was founded in 2017 and is headquartered in Scottsdale, Arizona.